US6765087B1
(en)
|
1992-08-21 |
2004-07-20 |
Vrije Universiteit Brussel |
Immunoglobulins devoid of light chains
|
CN1451043A
(en)
|
2000-06-29 |
2003-10-22 |
艾博特公司 |
Dual specificity antibodies and methods of making and using
|
GB0115256D0
(en)
|
2001-06-21 |
2001-08-15 |
Babraham Inst |
Mouse light chain locus
|
JP2005289809A
(en)
|
2001-10-24 |
2005-10-20 |
Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) |
Mutant heavy-chain antibody
|
AU2003227504A1
(en)
*
|
2002-04-15 |
2003-10-27 |
Chugai Seiyaku Kabushiki Kaisha |
METHOD OF CONSTRUCTING scDb LIBRARY
|
US9321832B2
(en)
|
2002-06-28 |
2016-04-26 |
Domantis Limited |
Ligand
|
US9028822B2
(en)
|
2002-06-28 |
2015-05-12 |
Domantis Limited |
Antagonists against TNFR1 and methods of use therefor
|
JP2006512895A
(en)
*
|
2002-06-28 |
2006-04-20 |
ドマンティス リミテッド |
Ligand
|
US20080241166A1
(en)
*
|
2002-06-28 |
2008-10-02 |
Domantis Limited |
Ligands that bind a receptor
|
US20060002935A1
(en)
|
2002-06-28 |
2006-01-05 |
Domantis Limited |
Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor
|
AU2003256299A1
(en)
*
|
2002-07-01 |
2004-01-19 |
Human Genome Sciences, Inc. |
Antibodies that specifically bind to reg iv
|
USRE47770E1
(en)
|
2002-07-18 |
2019-12-17 |
Merus N.V. |
Recombinant production of mixtures of antibodies
|
CN101537180B
(en)
|
2002-07-18 |
2016-02-10 |
莫鲁斯有限公司 |
The recombinant production of mixtures of antibodies
|
EP2390268B1
(en)
*
|
2002-11-08 |
2017-11-01 |
Ablynx N.V. |
Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
|
US9320792B2
(en)
|
2002-11-08 |
2016-04-26 |
Ablynx N.V. |
Pulmonary administration of immunoglobulin single variable domains and constructs thereof
|
US20060034845A1
(en)
*
|
2002-11-08 |
2006-02-16 |
Karen Silence |
Single domain antibodies directed against tumor necrosis factor alpha and uses therefor
|
AU2003286002B2
(en)
*
|
2002-11-08 |
2011-06-16 |
Ablynx N.V. |
Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
|
US20060034833A1
(en)
*
|
2002-11-08 |
2006-02-16 |
Els Beirnaert |
Single domain antibodies directed against interferron-gamma and uses therefor
|
ES2655912T3
(en)
*
|
2002-11-08 |
2018-02-22 |
Ablynx N.V. |
Single domain antibodies directed against tumor necrosis factor-alpha and uses for them
|
US20100003253A1
(en)
*
|
2002-11-08 |
2010-01-07 |
Ablynx N.V. |
Single domain antibodies directed against epidermal growth factor receptor and uses therefor
|
GB0230201D0
(en)
*
|
2002-12-27 |
2003-02-05 |
Domantis Ltd |
Retargeting
|
US8337841B2
(en)
*
|
2003-01-21 |
2012-12-25 |
Chugai Seiyaku Kabushiki Kaisha |
Methods of screening for antibody light chains
|
WO2004101790A1
(en)
*
|
2003-05-14 |
2004-11-25 |
Domantis Limited |
A process for recovering polypeptides that unfold reversibly from a polypeptide repertoire
|
US20100069614A1
(en)
|
2008-06-27 |
2010-03-18 |
Merus B.V. |
Antibody producing non-human mammals
|
ES2408582T3
(en)
|
2003-05-30 |
2013-06-21 |
Merus B.V. |
Fab library for the preparation of a mixture of antibodies
|
US8597911B2
(en)
*
|
2003-06-11 |
2013-12-03 |
Chugai Seiyaku Kabushiki Kaisha |
Process for producing antibodies
|
ATE414106T1
(en)
*
|
2003-06-30 |
2008-11-15 |
Domantis Ltd |
PEGYLATED SINGLE DOMAIN ANTIBODIES (DAB)
|
CA2549840C
(en)
|
2003-12-09 |
2012-03-20 |
Engeneic Molecular Delivery Pty Ltd. |
Targeted gene delivery to non-phagocytic mammalian cells via bacterially derived intact minicells
|
TW200530269A
(en)
|
2003-12-12 |
2005-09-16 |
Chugai Pharmaceutical Co Ltd |
Anti-Mpl antibodies
|
JPWO2005056602A1
(en)
*
|
2003-12-12 |
2008-03-06 |
中外製薬株式会社 |
Screening method for modified antibodies having agonist activity
|
JPWO2005056605A1
(en)
*
|
2003-12-12 |
2007-12-06 |
中外製薬株式会社 |
Modified antibody that recognizes a trimer or higher receptor
|
US7235641B2
(en)
*
|
2003-12-22 |
2007-06-26 |
Micromet Ag |
Bispecific antibodies
|
DK1737971T3
(en)
*
|
2004-01-20 |
2017-11-13 |
Merus Nv |
MIXTURES OF BINDING PROTEINS
|
AU2005250216B2
(en)
*
|
2004-06-01 |
2009-12-10 |
Domantis Limited |
Bispecific fusion antibodies with enhanced serum half-life
|
MX2007000921A
(en)
|
2004-07-22 |
2007-11-09 |
Univ Erasmus Medical Ct |
Binding molecules.
|
US7563443B2
(en)
|
2004-09-17 |
2009-07-21 |
Domantis Limited |
Monovalent anti-CD40L antibody polypeptides and compositions thereof
|
RU2401842C2
(en)
|
2004-10-08 |
2010-10-20 |
Домантис Лимитед |
Antagonists and method of using said antagonists
|
CN101133084A
(en)
*
|
2004-12-02 |
2008-02-27 |
多曼蒂斯有限公司 |
Anti-il-1r1 single domain antibodies and therapeutic uses
|
JP2008521426A
(en)
*
|
2004-12-02 |
2008-06-26 |
ドマンティス リミテッド |
PLAD domain peptide with increased serum half-life by conjugation to domain antibody
|
JP5185624B2
(en)
*
|
2004-12-02 |
2013-04-17 |
ドマンティス リミテッド |
Bispecific antibodies targeting serum albumin and GLP-1 or PYY
|
CA2598833A1
(en)
|
2005-03-03 |
2006-09-08 |
Curt W. Bradshaw |
Anti-angiogenic compounds
|
WO2006106905A1
(en)
|
2005-03-31 |
2006-10-12 |
Chugai Seiyaku Kabushiki Kaisha |
Process for production of polypeptide by regulation of assembly
|
JP5057967B2
(en)
*
|
2005-03-31 |
2012-10-24 |
中外製薬株式会社 |
sc (Fv) 2 structural isomer
|
MX363423B
(en)
|
2005-05-18 |
2019-03-22 |
Ablynx Nv |
Improved nanobodies against tumor necrosis factor-alpha.
|
DE102005023617A1
(en)
|
2005-05-21 |
2006-11-23 |
Aspre Ag |
Method for mixing colors in a display
|
JP2007008925A
(en)
*
|
2005-05-31 |
2007-01-18 |
Canon Inc |
Target substance-catching molecule
|
CA2610987C
(en)
*
|
2005-06-10 |
2013-09-10 |
Chugai Seiyaku Kabushiki Kaisha |
Stabilizer for protein preparation comprising meglumine and use thereof
|
EP1900814A4
(en)
*
|
2005-06-10 |
2010-07-21 |
Chugai Pharmaceutical Co Ltd |
sc(Fv)2 SITE-DIRECTED MUTANT
|
CN101262885B
(en)
|
2005-06-10 |
2015-04-01 |
中外制药株式会社 |
Pharmaceutical compositions containing sc(Fv)2
|
AR056806A1
(en)
|
2005-11-14 |
2007-10-24 |
Amgen Inc |
RANKL- PTH / PTHRP ANTIBODY CHEMICAL MOLECULES
|
CA2632866A1
(en)
*
|
2005-12-01 |
2007-06-07 |
Domantis Limited |
Noncompetitive domain antibody formats that bind interleukin 1 receptor type 1
|
EP1806365A1
(en)
|
2006-01-05 |
2007-07-11 |
Boehringer Ingelheim International GmbH |
Antibody molecules specific for fibroblast activation protein and immunoconjugates containing them
|
EP1999147A1
(en)
*
|
2006-03-27 |
2008-12-10 |
Ablynx N.V. |
Medical delivery device for therapeutic proteins based on single domain antibodies
|
DK2009101T3
(en)
*
|
2006-03-31 |
2018-01-15 |
Chugai Pharmaceutical Co Ltd |
Antibody modification method for purification of a bispecific antibody
|
GB0611116D0
(en)
|
2006-06-06 |
2006-07-19 |
Oxford Genome Sciences Uk Ltd |
Proteins
|
EP2074144A4
(en)
|
2006-09-05 |
2011-03-16 |
Medarex Inc |
Antibodies to bone morphogenic proteins and receptors therefor and methods for their use
|
CN101528259B
(en)
|
2006-10-02 |
2014-04-09 |
梅达雷克斯有限责任公司 |
Human antibodies that bind cxcr4 and uses thereof
|
US7767206B2
(en)
|
2006-10-02 |
2010-08-03 |
Amgen Inc. |
Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto
|
GB0621513D0
(en)
|
2006-10-30 |
2006-12-06 |
Domantis Ltd |
Novel polypeptides and uses thereof
|
JP4897050B2
(en)
|
2006-11-10 |
2012-03-14 |
コヴェックス・テクノロジーズ・アイルランド・リミテッド |
Antiangiogenic compounds
|
MX2009005776A
(en)
|
2006-12-01 |
2009-06-10 |
Medarex Inc |
Human antibodies that bind cd22 and uses thereof.
|
CL2007003622A1
(en)
|
2006-12-13 |
2009-08-07 |
Medarex Inc |
Human anti-cd19 monoclonal antibody; composition comprising it; and tumor cell growth inhibition method.
|
AU2007333098A1
(en)
|
2006-12-14 |
2008-06-19 |
Medarex, Inc. |
Human antibodies that bind CD70 and uses thereof
|
US20100062004A1
(en)
|
2006-12-19 |
2010-03-11 |
Ablynx N.V. |
Amino acid sequences directed against gpcrs and polypeptides comprising the same for the treatment of gpcr-related diseases and disorders
|
EP2102244A2
(en)
|
2006-12-19 |
2009-09-23 |
Ablynx N.V. |
Amino acid sequences directed against a metalloproteinase from the adam family and polypeptides comprising the same for the treatment of adam-related diseases and disorders
|
US8324350B2
(en)
|
2006-12-29 |
2012-12-04 |
Abbott Laboratories |
Dual-specific IL-1α/IL-1β antibodies
|
DK2447719T3
(en)
|
2007-02-26 |
2016-10-10 |
Oxford Biotherapeutics Ltd |
proteins
|
WO2008104803A2
(en)
|
2007-02-26 |
2008-09-04 |
Oxford Genome Sciences (Uk) Limited |
Proteins
|
CN101801407B
(en)
|
2007-06-05 |
2013-12-18 |
耶鲁大学 |
Inhibitors of receptor tyrosine kinases and methods of use thereof
|
CA2688434A1
(en)
|
2007-06-06 |
2008-12-11 |
Domantis Limited |
Polypeptides, antibody variable domains and antagonists
|
PE20090368A1
(en)
|
2007-06-19 |
2009-04-28 |
Boehringer Ingelheim Int |
ANTI-IGF ANTIBODIES
|
EP2195341B1
(en)
|
2007-09-26 |
2017-03-22 |
UCB Biopharma SPRL |
Dual specificity antibody fusions
|
AU2008329529B2
(en)
|
2007-11-27 |
2015-02-19 |
The University Of British Columbia |
14-3-3 eta antibodies and uses thereof for the diagnosis and treatment of arthritis
|
PT2851374T
(en)
|
2007-12-14 |
2017-06-20 |
Pfizer |
Binding molecules to the human ox40 receptor
|
AU2009212747B2
(en)
|
2008-01-31 |
2013-11-07 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Engineered antibody constant domain molecules
|
CA2720763A1
(en)
|
2008-04-07 |
2009-10-15 |
Ablynx Nv |
Amino acid sequences directed against the notch pathways and uses thereof
|
CN107488228A
(en)
|
2008-04-11 |
2017-12-19 |
中外制药株式会社 |
The antigen binding molecules combined repeatedly with the antigen of multiple molecules
|
US9188584B2
(en)
|
2008-06-18 |
2015-11-17 |
California Institute Of Technology |
Capture agents and related compositions, methods and systems
|
AU2009270726B2
(en)
|
2008-07-18 |
2015-07-09 |
Bristol-Myers Squibb Company |
Compositions monovalent for CD28 binding and methods of use
|
ES2752025T3
(en)
|
2008-07-25 |
2020-04-02 |
Wagner Richard W |
Protein screening methods
|
WO2010035012A1
(en)
*
|
2008-09-26 |
2010-04-01 |
Ucb Pharma S.A. |
Biological products
|
MX345226B
(en)
|
2008-10-29 |
2017-01-20 |
Ablynx Nv |
Formulations of single domain antigen binding molecules.
|
KR20110079693A
(en)
*
|
2008-10-29 |
2011-07-07 |
와이어쓰 엘엘씨 |
Methods for purification of single domain antigen binding molecules
|
CN103396488A
(en)
|
2008-12-12 |
2013-11-20 |
贝林格尔.英格海姆国际有限公司 |
Anti-IGF antibodies
|
AU2010207552A1
(en)
|
2009-01-21 |
2011-09-01 |
Oxford Biotherapeutics Ltd. |
PTA089 protein
|
WO2010085590A1
(en)
|
2009-01-23 |
2010-07-29 |
Biosynexus Incorporated |
Opsonic and protective antibodies specific for lipoteichoic acid gram positive bacteria
|
EA022925B1
(en)
|
2009-02-19 |
2016-03-31 |
Глаксо Груп Лимитед |
Improved anti-tnfr1 polypeptides, antibody variable domains & antagonists
|
EA028336B1
(en)
|
2009-03-05 |
2017-11-30 |
МЕДАРЕКС Л.Л.Си. |
Fully human antibodies specific to cadm1
|
AU2010233658B2
(en)
|
2009-04-10 |
2013-11-28 |
Ablynx Nv |
Improved amino acid sequences directed against IL-6R and polypeptides comprising the same for the treatment of IL-6R related diseases and disorders
|
NZ616382A
(en)
|
2009-04-20 |
2015-04-24 |
Oxford Biotherapeutics Ltd |
Antibodies specific to cadherin-17
|
WO2010122090A1
(en)
|
2009-04-24 |
2010-10-28 |
Glaxo Group Limited |
Fgfr1c antibody combinations
|
NZ597314A
(en)
|
2009-06-05 |
2013-07-26 |
Ablynx Nv |
Monovalent, bivalent and trivalent anti human respiratory syncytial virus (hrsv) nanobody constructs for the prevention and/or treatment of respiratory tract infections
|
WO2011006914A2
(en)
|
2009-07-16 |
2011-01-20 |
Glaxo Group Limited |
Antagonists, uses & methods for partially inhibiting tnfr1
|
KR20120063475A
(en)
|
2009-07-29 |
2012-06-15 |
글락소 그룹 리미티드 |
Anti-tgf-beta receptor type ii single domain antibodies
|
US20110172398A1
(en)
|
2009-10-02 |
2011-07-14 |
Boehringer Ingelheim International Gmbh |
Bispecific binding molecules for anti-angiogenesis therapy
|
US20110195494A1
(en)
|
2009-10-02 |
2011-08-11 |
Boehringer Ingelheim International Gmbh |
Dll4-binging molecules
|
TW201117824A
(en)
|
2009-10-12 |
2011-06-01 |
Amgen Inc |
Use of IL-17 receptor a antigen binding proteins
|
US20120231004A1
(en)
|
2009-10-13 |
2012-09-13 |
Oxford Biotherapeutic Ltd. |
Antibodies
|
PE20121564A1
(en)
|
2009-10-27 |
2012-11-29 |
Glaxo Group Ltd |
STABLE ANTI-TNFR1 POLYPEPTIDES, VARIABLE DOMAINS OF ANTIBODIES AND ANTAGONISTS
|
US20120282177A1
(en)
|
2009-11-02 |
2012-11-08 |
Christian Rohlff |
ROR1 as Therapeutic and Diagnostic Target
|
JP2013509869A
(en)
|
2009-11-05 |
2013-03-21 |
ノバルティス アーゲー |
Biomarkers for predicting fibrosis progression
|
EP2507262A1
(en)
|
2009-11-30 |
2012-10-10 |
Ablynx N.V. |
Improved amino acid sequences directed against human respiratory syncytial virus (hrsv) and polypeptides comprising the same for the prevention and/or treatment of respiratory tract infections
|
CN110079550A
(en)
|
2009-12-10 |
2019-08-02 |
瑞泽恩制药公司 |
Produce the mouse of heavy chain antibody
|
US8962807B2
(en)
|
2009-12-14 |
2015-02-24 |
Ablynx N.V. |
Single variable domain antibodies against OX40L, constructs and therapeutic use
|
WO2011083141A2
(en)
|
2010-01-08 |
2011-07-14 |
Ablynx Nv |
Method for generation of immunoglobulin sequences by using lipoprotein particles
|
ES2603559T5
(en)
|
2010-02-08 |
2021-02-22 |
Regeneron Pharma |
Mouse common light chain
|
US9796788B2
(en)
|
2010-02-08 |
2017-10-24 |
Regeneron Pharmaceuticals, Inc. |
Mice expressing a limited immunoglobulin light chain repertoire
|
US20130045492A1
(en)
|
2010-02-08 |
2013-02-21 |
Regeneron Pharmaceuticals, Inc. |
Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
|
US9120855B2
(en)
|
2010-02-10 |
2015-09-01 |
Novartis Ag |
Biologic compounds directed against death receptor 5
|
JP2013519869A
(en)
|
2010-02-10 |
2013-05-30 |
ノバルティス アーゲー |
Methods and compounds for muscle growth
|
US20130012916A1
(en)
|
2010-02-11 |
2013-01-10 |
Glide Pharmaceutical Technologies Limited |
Delivery of immunoglobulin variable domains and constructs thereof
|
JP5826194B2
(en)
|
2010-03-03 |
2015-12-02 |
アブリンクス ナームローゼ フェンノートシャップ |
Biparatopic A-beta binding polypeptide
|
TWI667257B
(en)
|
2010-03-30 |
2019-08-01 |
中外製藥股份有限公司 |
Antibodies with modified affinity to fcrn that promote antigen clearance
|
EP2560992A2
(en)
|
2010-04-21 |
2013-02-27 |
Glaxo Group Limited |
Binding domains
|
SG185415A1
(en)
|
2010-05-06 |
2012-12-28 |
Novartis Ag |
Compositions and methods of use for therapeutic low density lipoprotein - related protein 6 (lrp6) multivalent antibodies
|
ES2659406T3
(en)
|
2010-05-06 |
2018-03-15 |
Novartis Ag |
Compositions and methods of use for therapeutic antibodies against protein 6 related to low density lipoproteins (LRP6)
|
NZ603570A
(en)
|
2010-05-20 |
2014-12-24 |
Ablynx Nv |
Biological materials related to her3
|
WO2011161263A1
(en)
|
2010-06-25 |
2011-12-29 |
Ablynx Nv |
Pharmaceutical compositions for cutaneous administration
|
CN113150121A
(en)
|
2010-08-02 |
2021-07-23 |
瑞泽恩制药公司 |
Mice that make binding proteins comprising VL domains
|
AU2011288412A1
(en)
|
2010-08-13 |
2013-02-21 |
Medimmune Limited |
Monomeric polypeptides comprising variant Fc regions and methods of use
|
WO2012022734A2
(en)
|
2010-08-16 |
2012-02-23 |
Medimmune Limited |
Anti-icam-1 antibodies and methods of use
|
JP6057896B2
(en)
|
2010-08-20 |
2017-01-11 |
ノバルティス アーゲー |
Antibody to epidermal growth factor receptor 3 (HER3)
|
US20120225081A1
(en)
|
2010-09-03 |
2012-09-06 |
Boehringer Ingelheim International Gmbh |
Vegf-binding molecules
|
RU2551963C2
(en)
|
2010-09-09 |
2015-06-10 |
Пфайзер Инк. |
Molecules binding to 4-1bb
|
GB201016494D0
(en)
|
2010-09-30 |
2010-11-17 |
Queen Mary Innovation Ltd |
Polypeptide
|
AR083784A1
(en)
|
2010-11-08 |
2013-03-20 |
Novartis Ag |
LINK POLYPEPTIDES OF CHEMIOKIN RECEPTORS
|
US20130273055A1
(en)
|
2010-11-16 |
2013-10-17 |
Eric Borges |
Agents and methods for treating diseases that correlate with bcma expression
|
RU2658504C9
(en)
|
2010-11-30 |
2018-08-21 |
Чугаи Сейяку Кабусики Кайся |
Antigen-binding molecule, that is capable of multiple binding with a lot of antigenic molecules
|
WO2012085064A1
(en)
|
2010-12-23 |
2012-06-28 |
Roche Diagnostics Gmbh |
Detection of a posttranslationally modified polypeptide by a bi-valent binding agent
|
EP2655413B1
(en)
|
2010-12-23 |
2019-01-16 |
F.Hoffmann-La Roche Ag |
Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
|
WO2012093125A1
(en)
|
2011-01-06 |
2012-07-12 |
Glaxo Group Limited |
Ligands that bind tgf-beta receptor ii
|
EP3539991A1
(en)
|
2011-01-07 |
2019-09-18 |
Chugai Seiyaku Kabushiki Kaisha |
Method for improving physical properties of antibody
|
US20130310281A1
(en)
|
2011-02-02 |
2013-11-21 |
Glaxo Group Limited |
Novel antigen binding proteins
|
KR20230005405A
(en)
|
2011-02-25 |
2023-01-09 |
추가이 세이야쿠 가부시키가이샤 |
FcγRIIb-specific Fc antibody
|
US9133272B2
(en)
|
2011-03-01 |
2015-09-15 |
Amgen Inc. |
Bispecific binding agents
|
US20130078247A1
(en)
|
2011-04-01 |
2013-03-28 |
Boehringer Ingelheim International Gmbh |
Bispecific binding molecules binding to dii4 and ang2
|
US9527925B2
(en)
|
2011-04-01 |
2016-12-27 |
Boehringer Ingelheim International Gmbh |
Bispecific binding molecules binding to VEGF and ANG2
|
EP3103810A3
(en)
|
2011-04-21 |
2017-03-08 |
Garvan Institute of Medical Research |
Modified variable domain molecules and methods for producing and using them
|
UA117218C2
(en)
|
2011-05-05 |
2018-07-10 |
Мерк Патент Гмбх |
Amino acid sequences directed against il-17a, il-17f and/or il17-a/f and polypeptides comprising the same
|
EP2726506A1
(en)
|
2011-05-27 |
2014-05-07 |
Dutalys |
Removal of monomeric targets
|
CN103732625A
(en)
|
2011-05-27 |
2014-04-16 |
埃博灵克斯股份有限公司 |
Inhibition of bone resorption with RANKL binding peptides
|
EP2726510B1
(en)
*
|
2011-05-27 |
2023-03-08 |
F. Hoffmann-La Roche AG |
Dual targeting
|
US9580480B2
(en)
|
2011-05-31 |
2017-02-28 |
Massachusetts Institute Of Technology |
Cell-directed synthesis of multifunctional nanopatterns and nanomaterials
|
EP2723772A1
(en)
|
2011-06-23 |
2014-04-30 |
Ablynx N.V. |
Immunoglobulin single variable domains directed against ige
|
EP2726508B1
(en)
|
2011-06-28 |
2017-08-09 |
Oxford BioTherapeutics Ltd |
Antibodies to adp-ribosyl cyclase 2
|
WO2013001369A2
(en)
|
2011-06-28 |
2013-01-03 |
Oxford Biotherapeutics Ltd. |
Therapeutic and diagnostic target
|
AU2012275133B2
(en)
|
2011-06-30 |
2017-08-17 |
Genzyme Corporation |
Inhibitors of T-cell activation
|
DK2728002T3
(en)
|
2011-06-30 |
2022-04-04 |
Chugai Pharmaceutical Co Ltd |
HETERODIMERIZED POLYPEPTIDE
|
US20140234330A1
(en)
|
2011-07-22 |
2014-08-21 |
Amgen Inc. |
Il-17 receptor a is required for il-17c biology
|
SI3572517T1
(en)
|
2011-08-05 |
2021-09-30 |
Regeneron Pharmaceuticals, Inc. |
Humanized universal light chain mice
|
GB201116092D0
(en)
|
2011-09-16 |
2011-11-02 |
Bioceros B V |
Antibodies and uses thereof
|
US8987422B2
(en)
|
2011-09-22 |
2015-03-24 |
Amgen Inc. |
CD27L antigen binding proteins
|
WO2013048243A1
(en)
*
|
2011-09-29 |
2013-04-04 |
Apo-T B.V. |
Multi-specific binding molecules targeting aberrant cells
|
TW201817745A
(en)
|
2011-09-30 |
2018-05-16 |
日商中外製藥股份有限公司 |
Therapeutic antigen-binding molecule with a FcRn-binding domain that promotes antigen clearance
|
US20150050269A1
(en)
|
2011-09-30 |
2015-02-19 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-binding molecule promoting disappearance of antigens having plurality of biological activities
|
WO2013051294A1
(en)
|
2011-10-05 |
2013-04-11 |
中外製薬株式会社 |
Antigen-binding molecule for promoting clearance from plasma of antigen comprising saccharide chain receptor-binding domain
|
US20130122005A1
(en)
|
2011-10-27 |
2013-05-16 |
Paul Adam |
Anticancer combination therapy
|
ES2666856T3
(en)
|
2011-11-04 |
2018-05-08 |
Novartis Ag |
Protein 6 related to low density lipoproteins (LRP6) - half-life extender constructs
|
WO2013084148A2
(en)
|
2011-12-05 |
2013-06-13 |
Novartis Ag |
Antibodies for epidermal growth factor receptor 3 (her3) directed to domain ii of her3
|
CN108341873B
(en)
|
2011-12-05 |
2022-03-25 |
诺华股份有限公司 |
Antibodies to epidermal growth factor receptor 3(HER3)
|
KR102038974B1
(en)
|
2011-12-20 |
2019-10-31 |
리제너론 파마슈티칼스 인코포레이티드 |
Humanized light chain mice
|
SG11201404007WA
(en)
|
2012-01-13 |
2014-08-28 |
Apo T B V |
Aberrant cell-restricted immunoglobulins provided with a toxic moiety
|
CN113480639A
(en)
|
2012-02-09 |
2021-10-08 |
中外制药株式会社 |
Fc region variants of antibodies
|
CN115925938A
(en)
|
2012-02-27 |
2023-04-07 |
阿布林克斯有限公司 |
CX3CR1 binding polypeptides
|
EA031182B1
(en)
|
2012-03-30 |
2018-11-30 |
Бёрингер Ингельхайм Интернациональ Гмбх |
Ang2-BINDING MOLECULES
|
PT2838918T
(en)
|
2012-04-20 |
2019-08-23 |
Merus Nv |
Methods and means for the production of heterodimeric ig-like molecules
|
US9328174B2
(en)
|
2012-05-09 |
2016-05-03 |
Novartis Ag |
Chemokine receptor binding polypeptides
|
JO3623B1
(en)
|
2012-05-18 |
2020-08-27 |
Amgen Inc |
St2 antigen binding proteins
|
JP6628966B2
(en)
|
2012-06-14 |
2020-01-15 |
中外製薬株式会社 |
Antigen binding molecule containing an altered Fc region
|
GB201213652D0
(en)
|
2012-08-01 |
2012-09-12 |
Oxford Biotherapeutics Ltd |
Therapeutic and diagnostic target
|
WO2014030750A1
(en)
|
2012-08-24 |
2014-02-27 |
中外製薬株式会社 |
MOUSE FcγRII-SPECIFIC Fc ANTIBODY
|
KR20210084688A
(en)
|
2012-08-24 |
2021-07-07 |
추가이 세이야쿠 가부시키가이샤 |
FcγRIIb-specific Fc region variant
|
TW201425336A
(en)
|
2012-12-07 |
2014-07-01 |
Amgen Inc |
BCMA antigen binding proteins
|
EP2931749B1
(en)
|
2012-12-17 |
2019-04-24 |
Laboratoire Francais du Fractionnement et des Biotechnologies Societe Anonyme |
Use of monoclonal antibodies for the treatment of inflammation and bacterial infections
|
EP2940135B9
(en)
|
2012-12-27 |
2021-09-08 |
Chugai Seiyaku Kabushiki Kaisha |
Heterodimerized polypeptide
|
US9920121B2
(en)
|
2013-01-25 |
2018-03-20 |
Amgen Inc. |
Antibodies targeting CDH19 for melanoma
|
WO2014120916A1
(en)
|
2013-02-01 |
2014-08-07 |
Bristol-Myers Squibb Company |
Pegylated domain antibodies monovalent for cd28 binding and methods of use
|
GB201302447D0
(en)
|
2013-02-12 |
2013-03-27 |
Oxford Biotherapeutics Ltd |
Therapeutic and diagnostic target
|
JP2016508515A
(en)
|
2013-02-13 |
2016-03-22 |
ラボラトワール フランセ デュ フラクショヌマン エ デ ビオテクノロジーLaboratoire Francais du Fractionnement et des Biotechnologies |
Highly galactosylated anti-TNF-α antibody and use thereof
|
MX2015010429A
(en)
|
2013-02-13 |
2016-05-16 |
Lab Francais Du Fractionnement |
Cetuximab with modified glycosylation and uses thereof.
|
WO2014125377A2
(en)
|
2013-02-13 |
2014-08-21 |
Laboratoire Francais Du Fractionnement Et Des Biotechnologies |
Highly galactosylated anti-her2 antibodies and uses thereof
|
DK2962100T3
(en)
|
2013-02-28 |
2021-11-01 |
Caprion Proteomics Inc |
TUBERCULOSEBIOMARKEARS AND USES THEREOF
|
US20140255413A1
(en)
|
2013-03-07 |
2014-09-11 |
Boehringer Ingelheim International Gmbh |
Combination therapy for neoplasia treatment
|
EP2970479B1
(en)
|
2013-03-14 |
2019-04-24 |
Novartis AG |
Antibodies against notch 3
|
ES2872403T3
(en)
|
2013-03-14 |
2021-11-02 |
Childrens Medical Center |
Psap peptide for the treatment of cancers expressing CD36
|
US10993420B2
(en)
|
2013-03-15 |
2021-05-04 |
Erasmus University Medical Center |
Production of heavy chain only antibodies in transgenic mammals
|
HUE040234T2
(en)
|
2013-03-18 |
2019-02-28 |
Biocerox Prod Bv |
Humanized anti-cd134 (ox40) antibodies and uses thereof
|
EP3783017A1
(en)
|
2013-04-02 |
2021-02-24 |
Chugai Seiyaku Kabushiki Kaisha |
Fc region variant
|
MX2015013901A
(en)
*
|
2013-04-05 |
2015-12-11 |
Genentech Inc |
Anti-il-4 antibodies and bispecific antibodies and uses thereof.
|
SG10201800492PA
(en)
|
2013-04-29 |
2018-03-28 |
Hoffmann La Roche |
Human fcrn-binding modified antibodies and methods of use
|
PL2992010T3
(en)
|
2013-04-29 |
2021-08-23 |
F.Hoffmann-La Roche Ag |
Fc-receptor binding modified asymmetric antibodies and methods of use
|
HUE056580T2
(en)
|
2013-05-30 |
2022-02-28 |
Kiniksa Pharmaceuticals Ltd |
Oncostatin m receptor antigen binding proteins
|
CN106211774B
(en)
|
2013-08-02 |
2020-11-06 |
辉瑞公司 |
anti-CXCR 4 antibodies and antibody-drug conjugates
|
BR112016006197B1
(en)
|
2013-09-27 |
2023-04-11 |
Chugai Seiyaku Kabushiki Kaisha |
METHOD FOR PRODUCING A BISPECIFIC POLYPEPTIDE ANTIBODY
|
WO2015050959A1
(en)
|
2013-10-01 |
2015-04-09 |
Yale University |
Anti-kit antibodies and methods of use thereof
|
EP3733244A1
(en)
|
2013-10-02 |
2020-11-04 |
Medlmmune, LLC |
Neutralizing anti-influenza a antibodies and uses thereof
|
WO2015054691A2
(en)
|
2013-10-11 |
2015-04-16 |
The United States Of America, As Pepresented By The Secretary, Department Of Health And Human Services |
Tem8 antibodies and their use
|
JP6657098B2
(en)
|
2013-10-21 |
2020-03-04 |
ダイアックス コーポレーション |
Diagnosis and treatment of autoimmune diseases
|
MX2016006529A
(en)
*
|
2013-12-20 |
2016-08-03 |
Genentech Inc |
Dual specific antibodies.
|
WO2015103549A1
(en)
|
2014-01-03 |
2015-07-09 |
The United States Of America, As Represented By The Secretary Department Of Health And Human Services |
Neutralizing antibodies to hiv-1 env and their use
|
JP6786392B2
(en)
|
2014-01-15 |
2020-11-18 |
エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft |
Fc region mutant with modified FcRn binding properties and retained protein A binding properties
|
JOP20200094A1
(en)
|
2014-01-24 |
2017-06-16 |
Dana Farber Cancer Inst Inc |
Antibody molecules to pd-1 and uses thereof
|
JOP20200096A1
(en)
|
2014-01-31 |
2017-06-16 |
Children’S Medical Center Corp |
Antibody molecules to tim-3 and uses thereof
|
US9701743B2
(en)
|
2014-02-20 |
2017-07-11 |
Allergan, Inc. |
Complement component C5 antibodies
|
KR20160126054A
(en)
|
2014-02-27 |
2016-11-01 |
알러간, 인코포레이티드 |
COMPLEMENT FACTOR Bb ANTIBODIES
|
CU24481B1
(en)
|
2014-03-14 |
2020-03-04 |
Immutep Sas |
ANTIBODY MOLECULES THAT JOIN LAG-3
|
US20170335281A1
(en)
|
2014-03-15 |
2017-11-23 |
Novartis Ag |
Treatment of cancer using chimeric antigen receptor
|
CA2941514A1
(en)
|
2014-03-21 |
2015-09-24 |
Regeneron Pharmaceuticals, Inc. |
Vl antigen binding proteins exhibiting distinct binding characteristics
|
CA2942697A1
(en)
|
2014-03-21 |
2015-09-24 |
Lynn Macdonald |
Non-human animals that make single domain binding proteins
|
EP3134737A4
(en)
|
2014-04-24 |
2018-01-17 |
Immusant Inc. |
Methods of diagnosis and treatment of celiac disease in children
|
EP4043011A1
(en)
|
2014-05-16 |
2022-08-17 |
Children's Hospital Medical Center |
Methods for assessing responsiveness to asthma treatment based on vnn-1 expression and promoter methylation
|
NL2013661B1
(en)
|
2014-10-21 |
2016-10-05 |
Ablynx Nv |
KV1.3 Binding immunoglobulins.
|
BR112016030740A2
(en)
|
2014-07-01 |
2018-02-20 |
Pfizer Inc. |
bispecific heterodimeric bodies and their uses
|
JP2017528433A
(en)
|
2014-07-21 |
2017-09-28 |
ノバルティス アーゲー |
Low immunoenhancing dose of mTOR inhibitor and CAR combination
|
EP3172237A2
(en)
|
2014-07-21 |
2017-05-31 |
Novartis AG |
Treatment of cancer using humanized anti-bcma chimeric antigen receptor
|
AU2015292755B2
(en)
|
2014-07-21 |
2020-11-12 |
Novartis Ag |
Treatment of cancer using a CD33 chimeric antigen receptor
|
US11542488B2
(en)
|
2014-07-21 |
2023-01-03 |
Novartis Ag |
Sortase synthesized chimeric antigen receptors
|
EP3174546B1
(en)
|
2014-07-31 |
2019-10-30 |
Novartis AG |
Subset-optimized chimeric antigen receptor-containing t-cells
|
US10851149B2
(en)
|
2014-08-14 |
2020-12-01 |
The Trustees Of The University Of Pennsylvania |
Treatment of cancer using GFR α-4 chimeric antigen receptor
|
MY189028A
(en)
|
2014-08-19 |
2022-01-20 |
Novartis Ag |
Anti-cd123 chimeric antigen receptor (car) for use in cancer treatment
|
AU2015317608B2
(en)
|
2014-09-17 |
2021-03-11 |
Novartis Ag |
Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
|
TWI716362B
(en)
|
2014-10-14 |
2021-01-21 |
瑞士商諾華公司 |
Antibody molecules to pd-l1 and uses thereof
|
WO2016061509A1
(en)
|
2014-10-17 |
2016-04-21 |
The Broad Institute, Inc. |
Compositions and methods of treatng muscular dystrophy
|
SI3215528T1
(en)
|
2014-11-06 |
2019-11-29 |
Hoffmann La Roche |
Fc-region variants with modified fcrn-binding and methods of use
|
US10160795B2
(en)
|
2014-11-14 |
2018-12-25 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Neutralizing antibodies to Ebola virus glycoprotein and their use
|
US20180334490A1
(en)
|
2014-12-03 |
2018-11-22 |
Qilong H. Wu |
Methods for b cell preconditioning in car therapy
|
US11897921B2
(en)
|
2014-12-09 |
2024-02-13 |
New York University |
Propeptide fusion comprising a mutated clostridium botulinum neurotoxin and a VHH domain
|
EP3261665A1
(en)
|
2015-02-24 |
2018-01-03 |
The United States of America, as represented by The Secretary, Department of Health and Human Services |
Middle east respiratory syndrome coronavirus immunogens, antibodies, and their use
|
EP3271403A1
(en)
|
2015-03-19 |
2018-01-24 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals that select for light chain variable regions that bind antigen
|
WO2016154003A1
(en)
|
2015-03-20 |
2016-09-29 |
The United States Of America, As Represented By The Secretary, Department Of Health & Human Services |
Neutralizing antibodies to gp120 and their use
|
SG11201708191XA
(en)
|
2015-04-08 |
2017-11-29 |
Novartis Ag |
Cd20 therapies, cd22 therapies, and combination therapies with a cd19 chimeric antigen receptor (car) - expressing cell
|
EP3286211A1
(en)
|
2015-04-23 |
2018-02-28 |
Novartis AG |
Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
|
WO2016196975A1
(en)
|
2015-06-03 |
2016-12-08 |
The United States Of America, As Represented By The Secretary Department Of Health & Human Services |
Neutralizing antibodies to hiv-1 env and their use
|
EP3313519B1
(en)
|
2015-06-29 |
2023-05-31 |
Children's Medical Center Corporation |
Jak-stat inhibitors for the treatment of congenital myopathies
|
US20180207273A1
(en)
|
2015-07-29 |
2018-07-26 |
Novartis Ag |
Combination therapies comprising antibody molecules to tim-3
|
PT3317301T
(en)
|
2015-07-29 |
2021-07-09 |
Novartis Ag |
Combination therapies comprising antibody molecules to lag-3
|
US10746739B2
(en)
|
2015-09-14 |
2020-08-18 |
Leukemia Therapeutics, LLC |
Identification of novel diagnostics and therapeutics by modulating RhoH
|
CN108884149B
(en)
|
2015-11-03 |
2022-07-01 |
美国政府(由卫生和人类服务部的部长所代表) |
HIV-1 GP41 neutralizing antibodies and uses thereof
|
TN2018000180A1
(en)
|
2015-11-27 |
2019-10-04 |
Ablynx Nv |
Polypeptides inhibiting cd40l
|
LT3383425T
(en)
|
2015-12-04 |
2020-10-12 |
Boehringer Ingelheim International Gmbh |
Biparatopic polypeptides antagonizing wnt signaling in tumor cells
|
CA3007421A1
(en)
|
2015-12-17 |
2017-06-22 |
Novartis Ag |
Combination of c-met inhibitor with antibody molecule to pd-1 and uses thereof
|
JP2019503349A
(en)
|
2015-12-17 |
2019-02-07 |
ノバルティス アーゲー |
Antibody molecules against PD-1 and uses thereof
|
US20200270363A1
(en)
|
2015-12-25 |
2020-08-27 |
Chugai Seiyaku Kabushiki Kaisha |
Antibody having enhanced activity, and method for modifying same
|
EP3398965A4
(en)
|
2015-12-28 |
2019-09-18 |
Chugai Seiyaku Kabushiki Kaisha |
Method for promoting efficiency of purification of fc region-containing polypeptide
|
EP3851457A1
(en)
|
2016-01-21 |
2021-07-21 |
Novartis AG |
Multispecific molecules targeting cll-1
|
US20200281973A1
(en)
|
2016-03-04 |
2020-09-10 |
Novartis Ag |
Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore
|
US11549099B2
(en)
|
2016-03-23 |
2023-01-10 |
Novartis Ag |
Cell secreted minibodies and uses thereof
|
US20190119387A1
(en)
|
2016-04-05 |
2019-04-25 |
Glaxosmithkline Intellectual Property Development Limited |
Inhibition of tgfbeta in immunotherapy
|
SI3443096T1
(en)
|
2016-04-15 |
2023-07-31 |
Novartis Ag |
Compositions and methods for selective expression of chimeric antigen receptors
|
WO2017192589A1
(en)
|
2016-05-02 |
2017-11-09 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Neutralizing antibodies to influenza ha and their use and identification
|
WO2017210617A2
(en)
|
2016-06-02 |
2017-12-07 |
Porter, David, L. |
Therapeutic regimens for chimeric antigen receptor (car)- expressing cells
|
WO2018013918A2
(en)
|
2016-07-15 |
2018-01-18 |
Novartis Ag |
Treatment and prevention of cytokine release syndrome using a chimeric antigen receptor in combination with a kinase inhibitor
|
KR20230100748A
(en)
|
2016-07-28 |
2023-07-05 |
노파르티스 아게 |
Combination therapies of chimeric antigen receptors adn pd-1 inhibitors
|
CN109661406A
(en)
|
2016-07-29 |
2019-04-19 |
国家医疗保健研究所 |
The antibody and application thereof of target tumor associated macrophages
|
US20190161542A1
(en)
|
2016-08-01 |
2019-05-30 |
Novartis Ag |
Treatment of cancer using a chimeric antigen receptor in combination with an inhibitor of a pro-m2 macrophage molecule
|
US11098113B2
(en)
|
2016-09-15 |
2021-08-24 |
Vib Vzw |
Immunoglobulin single variable domains directed against macrophage migration inhibitory factor
|
CN110225927B
(en)
|
2016-10-07 |
2024-01-12 |
诺华股份有限公司 |
Chimeric antigen receptor for the treatment of cancer
|
BR112019010061A2
(en)
|
2016-11-16 |
2019-08-13 |
Ablynx Nv |
t-cell recruitment polypeptides capable of binding to cd123 and tcr alpha / beta
|
ES2912408T3
(en)
|
2017-01-26 |
2022-05-25 |
Novartis Ag |
CD28 compositions and methods for therapy with chimeric receptors for antigens
|
CA3054623A1
(en)
|
2017-02-28 |
2018-09-07 |
Vib Vzw |
Means and methods for oral protein delivery
|
EP3589647A1
(en)
|
2017-02-28 |
2020-01-08 |
Novartis AG |
Shp inhibitor compositions and uses for chimeric antigen receptor therapy
|
US11274160B2
(en)
|
2017-03-02 |
2022-03-15 |
INSERM (Institut National de la Santé et de la Recherche Médicale |
Antibodies having specificity to Nectin-4 and uses thereof
|
US20210107994A1
(en)
|
2017-03-31 |
2021-04-15 |
Public University Corporation Nara Medical University |
Medicinal composition usable for preventing and/or treating blood coagulation factor ix abnormality, comprising multispecific antigen binding molecule replacing function of blood coagulation factor viii
|
EP3615068A1
(en)
|
2017-04-28 |
2020-03-04 |
Novartis AG |
Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
|
US20200055948A1
(en)
|
2017-04-28 |
2020-02-20 |
Novartis Ag |
Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
|
KR20200005635A
(en)
|
2017-05-11 |
2020-01-15 |
브이아이비 브이지더블유 |
Glycosylation of Variable Immunoglobulin Domains
|
CN110637030A
(en)
|
2017-05-31 |
2019-12-31 |
勃林格殷格翰国际有限公司 |
Polypeptide for antagonizing Wnt signaling in tumor cells
|
CA3064318A1
(en)
|
2017-06-02 |
2018-12-06 |
Merck Patent Gmbh |
Polypeptides binding adamts5, mmp13 and aggrecan
|
EP3630178A1
(en)
|
2017-06-02 |
2020-04-08 |
Merck Patent GmbH |
Mmp13 binding immunoglobulins
|
AU2018277343A1
(en)
|
2017-06-02 |
2020-01-02 |
Ablynx N.V. |
Adamts binding immunoglobulins
|
SG10202113337YA
(en)
|
2017-06-02 |
2021-12-30 |
Ablynx Nv |
Aggrecan binding immunoglobulins
|
EA202090104A1
(en)
|
2017-06-22 |
2020-04-09 |
Новартис Аг |
ANTIBODY MOLECULES TO CD73 AND WAYS OF THEIR APPLICATION
|
AU2018292618A1
(en)
|
2017-06-27 |
2019-12-19 |
Novartis Ag |
Dosage regimens for anti-TIM-3 antibodies and uses thereof
|
NZ760841A
(en)
|
2017-07-11 |
2024-02-23 |
Compass Therapeutics Llc |
Agonist antibodies that bind human cd137 and uses thereof
|
GB201711208D0
(en)
|
2017-07-12 |
2017-08-23 |
Iontas Ltd |
Ion channel inhibitors
|
CA3070253A1
(en)
|
2017-07-19 |
2019-01-24 |
Vib Vzw |
Serum albumin binding agents
|
CN111163798A
(en)
|
2017-07-20 |
2020-05-15 |
诺华股份有限公司 |
Dosing regimens for anti-LAG-3 antibodies and uses thereof
|
US11174322B2
(en)
|
2017-07-24 |
2021-11-16 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Antibodies and peptides to treat HCMV related diseases
|
WO2019036855A1
(en)
|
2017-08-21 |
2019-02-28 |
Adagene Inc. |
Anti-cd137 molecules and use thereof
|
US11718679B2
(en)
|
2017-10-31 |
2023-08-08 |
Compass Therapeutics Llc |
CD137 antibodies and PD-1 antagonists and uses thereof
|
KR20200091400A
(en)
|
2017-10-31 |
2020-07-30 |
브이아이비 브이지더블유 |
Novel antigen-binding chimeric proteins and methods and uses thereof
|
US20210179709A1
(en)
|
2017-10-31 |
2021-06-17 |
Novartis Ag |
Anti-car compositions and methods
|
WO2019099838A1
(en)
|
2017-11-16 |
2019-05-23 |
Novartis Ag |
Combination therapies
|
EP3713961A2
(en)
|
2017-11-20 |
2020-09-30 |
Compass Therapeutics LLC |
Cd137 antibodies and tumor antigen-targeting antibodies and uses thereof
|
US11976109B2
(en)
|
2018-01-02 |
2024-05-07 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Neutralizing antibodies to ebola virus glycoprotein and their use
|
AU2019215031A1
(en)
|
2018-01-31 |
2020-08-20 |
Novartis Ag |
Combination therapy using a chimeric antigen receptor
|
WO2019148445A1
(en)
|
2018-02-02 |
2019-08-08 |
Adagene Inc. |
Precision/context-dependent activatable antibodies, and methods of making and using the same
|
WO2019148444A1
(en)
|
2018-02-02 |
2019-08-08 |
Adagene Inc. |
Anti-ctla4 antibodies and methods of making and using the same
|
WO2019166622A1
(en)
|
2018-03-01 |
2019-09-06 |
Vrije Universiteit Brussel |
Human pd-l1-binding immunoglobulins
|
US20210147547A1
(en)
|
2018-04-13 |
2021-05-20 |
Novartis Ag |
Dosage Regimens For Anti-Pd-L1 Antibodies And Uses Thereof
|
US20210047405A1
(en)
|
2018-04-27 |
2021-02-18 |
Novartis Ag |
Car t cell therapies with enhanced efficacy
|
WO2019226658A1
(en)
|
2018-05-21 |
2019-11-28 |
Compass Therapeutics Llc |
Multispecific antigen-binding compositions and methods of use
|
JP2021525243A
(en)
|
2018-05-21 |
2021-09-24 |
コンパス セラピューティクス リミテッド ライアビリティ カンパニー |
Compositions and Methods for Promoting Killing of Target Cells by NK Cells
|
WO2019227003A1
(en)
|
2018-05-25 |
2019-11-28 |
Novartis Ag |
Combination therapy with chimeric antigen receptor (car) therapies
|
US20210214459A1
(en)
|
2018-05-31 |
2021-07-15 |
Novartis Ag |
Antibody molecules to cd73 and uses thereof
|
JP7438988B2
(en)
|
2018-06-13 |
2024-02-27 |
ノバルティス アーゲー |
BCMA chimeric antigen receptor and its use
|
PE20210418A1
(en)
|
2018-06-19 |
2021-03-08 |
Atarga Llc |
COMPLEMENT COMPONENT 5 ANTIBODY MOLECULES AND THEIR USES
|
US11845797B2
(en)
|
2018-07-03 |
2023-12-19 |
Marengo Therapeutics, Inc. |
Anti-TCR antibody molecules and uses thereof
|
AR116109A1
(en)
|
2018-07-10 |
2021-03-31 |
Novartis Ag |
DERIVATIVES OF 3- (5-AMINO-1-OXOISOINDOLIN-2-IL) PIPERIDINE-2,6-DIONA AND USES OF THE SAME
|
CA3104142A1
(en)
|
2018-07-11 |
2020-01-16 |
Timothy Clyde GRANADE |
Monoclonal antibody for the detection of the antiretroviral drug emtricitabine (ftc, 2',3'-dideoxy-5-fluoro-3'-thiacytidine)
|
WO2020021465A1
(en)
|
2018-07-25 |
2020-01-30 |
Advanced Accelerator Applications (Italy) S.R.L. |
Method of treatment of neuroendocrine tumors
|
WO2020053122A1
(en)
|
2018-09-10 |
2020-03-19 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Combination of her2/neu antibody with heme for treating cancer
|
EP3636657A1
(en)
|
2018-10-08 |
2020-04-15 |
Ablynx N.V. |
Chromatography-free antibody purification method
|
US20210388084A1
(en)
|
2018-10-25 |
2021-12-16 |
Polpharma Biologics Utrecht B.V. |
Anti-human cd89 antibodies and uses thereof
|
AU2019379576A1
(en)
|
2018-11-13 |
2021-06-03 |
Compass Therapeutics Llc |
Multispecific binding constructs against checkpoint molecules and uses thereof
|
CN113194952A
(en)
|
2018-12-20 |
2021-07-30 |
诺华股份有限公司 |
Combination of an HDM2-P53 interaction inhibitor and a BCL 2inhibitor and use thereof for treating cancer
|
CA3123511A1
(en)
|
2018-12-20 |
2020-06-25 |
Novartis Ag |
Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
|
EP3883609A2
(en)
|
2018-12-20 |
2021-09-29 |
The United States of America, as represented by the Secretary, Department of Health and Human Services |
Ebola virus glycoprotein-specific monoclonal antibodies and uses thereof
|
CA3123519A1
(en)
|
2019-02-15 |
2020-08-20 |
Novartis Ag |
Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
US10871640B2
(en)
|
2019-02-15 |
2020-12-22 |
Perkinelmer Cellular Technologies Germany Gmbh |
Methods and systems for automated imaging of three-dimensional objects
|
WO2020165833A1
(en)
|
2019-02-15 |
2020-08-20 |
Novartis Ag |
3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
WO2020172553A1
(en)
|
2019-02-22 |
2020-08-27 |
Novartis Ag |
Combination therapies of egfrviii chimeric antigen receptors and pd-1 inhibitors
|
WO2020193520A1
(en)
|
2019-03-25 |
2020-10-01 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Treatment of taupathy disorders by targeting new tau species
|
US20220169706A1
(en)
|
2019-03-28 |
2022-06-02 |
Danisco Us Inc |
Engineered antibodies
|
EP3946593A1
(en)
|
2019-03-29 |
2022-02-09 |
Atarga, LLC |
Anti fgf23 antibody
|
US20220220197A1
(en)
|
2019-05-28 |
2022-07-14 |
Vib Vzw |
Cancer Treatment by Targeting Plexins in the Immune Compartment
|
EP3976067A1
(en)
|
2019-05-28 |
2022-04-06 |
Vib Vzw |
Cd8+ t-cells lacking plexins and their application in cancer treatment
|
CA3142833A1
(en)
|
2019-07-02 |
2021-01-07 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Monoclonal antibodies that bind egfrviii and their use
|
WO2021058729A1
(en)
|
2019-09-27 |
2021-04-01 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Anti-müllerian inhibiting substance type i receptor antibodies and uses thereof
|
CN114450304B
(en)
|
2019-09-27 |
2023-12-12 |
国家医疗保健研究所 |
anti-Mullera tube inhibiting substance antibodies and uses thereof
|
CN114786679A
(en)
|
2019-10-21 |
2022-07-22 |
诺华股份有限公司 |
Combination therapy with Vernetork and TIM-3 inhibitors
|
EP4048285A1
(en)
|
2019-10-21 |
2022-08-31 |
Novartis AG |
Tim-3 inhibitors and uses thereof
|
WO2021084104A1
(en)
|
2019-10-30 |
2021-05-06 |
Bioinvent International Ab |
Tetravalent antibody molecules
|
WO2021108661A2
(en)
|
2019-11-26 |
2021-06-03 |
Novartis Ag |
Chimeric antigen receptors and uses thereof
|
WO2021116119A1
(en)
|
2019-12-09 |
2021-06-17 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Antibodies having specificity to her4 and uses thereof
|
GB201918279D0
(en)
|
2019-12-12 |
2020-01-29 |
Vib Vzw |
Glycosylated single chain immunoglobulin domains
|
CN115175937A
(en)
|
2019-12-20 |
2022-10-11 |
诺华股份有限公司 |
Combination of anti-TIM-3 antibody MBG453 and anti-TGF-beta antibody NIS793 with or without decitabine or anti-PD-1 antibody, gabapentin, for the treatment of myelofibrosis and myelodysplastic syndrome
|
KR20220128363A
(en)
|
2019-12-24 |
2022-09-20 |
제이제이피 바이오로직스 에스피. 제트 오.오. |
Anti-human HVEM (TNFRSF14) antibodies and uses thereof
|
IL293752A
(en)
|
2020-01-17 |
2022-08-01 |
Novartis Ag |
Combination comprising a tim-3 inhibitor and a hypomethylating agent for use in treating myelodysplastic syndrome or chronic myelomonocytic leukemia
|
CN115298322A
(en)
|
2020-01-17 |
2022-11-04 |
贝克顿迪金森公司 |
Methods and compositions for single cell secretogomics
|
CN113248611A
(en)
|
2020-02-13 |
2021-08-13 |
湖南华康恒健生物技术有限公司 |
anti-BCMA antibody, pharmaceutical composition and application thereof
|
WO2021173995A2
(en)
|
2020-02-27 |
2021-09-02 |
Novartis Ag |
Methods of making chimeric antigen receptor-expressing cells
|
EP4139355A1
(en)
|
2020-04-21 |
2023-03-01 |
Jjp Biologics Sp. Z O.O. |
Humanized anti-human cd89 antibodies and uses thereof
|
WO2021228956A1
(en)
|
2020-05-12 |
2021-11-18 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
New method to treat cutaneous t-cell lymphomas and tfh derived lymphomas
|
WO2021229104A1
(en)
|
2020-05-15 |
2021-11-18 |
Université de Liège |
Anti-cd38 single-domain antibodies in disease monitoring and treatment
|
EP4155405A1
(en)
|
2020-05-22 |
2023-03-29 |
Chugai Seiyaku Kabushiki Kaisha |
Antibody for neutralizing substance having coagulation factor viii (f.viii) function-substituting activity
|
JP2023531676A
(en)
|
2020-06-23 |
2023-07-25 |
ノバルティス アーゲー |
Dosing Regimens Containing 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione Derivatives
|
US11524998B2
(en)
|
2020-07-16 |
2022-12-13 |
Novartis Ag |
Anti-betacellulin antibodies, fragments thereof, and multi-specific binding molecules
|
WO2022026592A2
(en)
|
2020-07-28 |
2022-02-03 |
Celltas Bio, Inc. |
Antibody molecules to coronavirus and uses thereof
|
WO2022029573A1
(en)
|
2020-08-03 |
2022-02-10 |
Novartis Ag |
Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
CN114106173A
(en)
|
2020-08-26 |
2022-03-01 |
上海泰槿生物技术有限公司 |
anti-OX 40 antibodies, pharmaceutical compositions and uses thereof
|
US20230312689A1
(en)
|
2020-08-26 |
2023-10-05 |
National University Corporation Kumamoto University |
Human antibody or antigen-binding fragment thereof against coronavirus spike protein
|
EP4204021A1
(en)
|
2020-08-31 |
2023-07-05 |
Advanced Accelerator Applications International S.A. |
Method of treating psma-expressing cancers
|
WO2022043558A1
(en)
|
2020-08-31 |
2022-03-03 |
Advanced Accelerator Applications International Sa |
Method of treating psma-expressing cancers
|
EP4216943A1
(en)
|
2020-09-24 |
2023-08-02 |
Vib Vzw |
Combination of p2y6 inhibitors and immune checkpoint inhibitors
|
WO2022063957A1
(en)
|
2020-09-24 |
2022-03-31 |
Vib Vzw |
Biomarker for anti-tumor therapy
|
EP4240765A2
(en)
|
2020-11-06 |
2023-09-13 |
Novartis AG |
Antibody fc variants
|
CN116635062A
(en)
|
2020-11-13 |
2023-08-22 |
诺华股份有限公司 |
Combination therapy using Chimeric Antigen Receptor (CAR) expressing cells
|
US20240141060A1
(en)
|
2021-01-29 |
2024-05-02 |
Novartis Ag |
Dosage regimes for anti-cd73 and anti-entpd2 antibodies and uses thereof
|
CN117241804A
(en)
|
2021-02-17 |
2023-12-15 |
非营利性组织佛兰芒综合大学生物技术研究所 |
Inhibition of SLC4A4 in cancer treatment
|
WO2022178255A2
(en)
|
2021-02-19 |
2022-08-25 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Single domain antibodies that neutralize sars-cov-2
|
TW202304979A
(en)
|
2021-04-07 |
2023-02-01 |
瑞士商諾華公司 |
USES OF ANTI-TGFβ ANTIBODIES AND OTHER THERAPEUTIC AGENTS FOR THE TREATMENT OF PROLIFERATIVE DISEASES
|
GB2623199A
(en)
|
2021-04-08 |
2024-04-10 |
Marengo Therapeutics Inc |
Multifunctional molecules binding to TCR and uses thereof
|
WO2022242892A1
(en)
|
2021-05-17 |
2022-11-24 |
Université de Liège |
Anti-cd38 single-domain antibodies in disease monitoring and treatment
|
AR125874A1
(en)
|
2021-05-18 |
2023-08-23 |
Novartis Ag |
COMBINATION THERAPIES
|
WO2023044483A2
(en)
|
2021-09-20 |
2023-03-23 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of her2 positive cancer
|
WO2023092004A1
(en)
|
2021-11-17 |
2023-05-25 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of tau-related disorders
|
US20230383010A1
(en)
|
2022-02-07 |
2023-11-30 |
Visterra, Inc. |
Anti-idiotype antibody molecules and uses thereof
|
WO2023175171A1
(en)
|
2022-03-18 |
2023-09-21 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Bk polyomavirus antibodies and uses thereof
|
WO2023220695A2
(en)
|
2022-05-13 |
2023-11-16 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of her2 positive cancer
|
WO2024008755A1
(en)
|
2022-07-04 |
2024-01-11 |
Vib Vzw |
Blood-cerebrospinal fluid barrier crossing antibodies
|
WO2024030976A2
(en)
|
2022-08-03 |
2024-02-08 |
Voyager Therapeutics, Inc. |
Compositions and methods for crossing the blood brain barrier
|
WO2024052503A1
(en)
|
2022-09-08 |
2024-03-14 |
Institut National de la Santé et de la Recherche Médicale |
Antibodies having specificity to ltbp2 and uses thereof
|
WO2024056668A1
(en)
|
2022-09-12 |
2024-03-21 |
Institut National de la Santé et de la Recherche Médicale |
New anti-itgb8 antibodies and its uses thereof
|
WO2024083843A1
(en)
|
2022-10-18 |
2024-04-25 |
Confo Therapeutics N.V. |
Amino acid sequences directed against the melanocortin 4 receptor and polypeptides comprising the same for the treatment of mc4r-related diseases and disorders
|